F. HOFFMANN-LA ROCHE AG Patent applications |
Patent application number | Title | Published |
20150299143 | SUBSTITUTED TRIAZOLE AND IMIDAZOLE COMPOUNDS - The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease. | 10-22-2015 |
20150031690 | FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES - The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. | 01-29-2015 |
20150017078 | Sample Handling System - Sample handling system for handling samples contained in tubes ( | 01-15-2015 |
20140315856 | AMINOPYRAZOLE DERIVATIVE - A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a C | 10-23-2014 |
20140314748 | ANTIBODY FORMULATIONS - The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations. | 10-23-2014 |
20140221367 | PHARMACEUTICAL COMPOUNDS - Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate. | 08-07-2014 |
20140154810 | METHOD FOR CONDUCTING PLATELET AGGREGATION ANALYSIS - A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyser. | 06-05-2014 |
20140039002 | SOLID FORMS OF A PHARMACEUTICALLY ACTIVE SUBSTANCE - The present invention provides solid forms of the compound of formula 1 and pharmaceutical uses thereof. (I) | 02-06-2014 |
20140038990 | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease - The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 02-06-2014 |
20130317022 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE - The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, | 11-28-2013 |
20130296807 | DRUG RECONSTITUTION AND DELIVERY DEVICE - A device for automatically delivering a drug to a user and method thereof are disclosed. The device ( | 11-07-2013 |
20130292004 | DEVICES AND METHODS FOR AUTOMATICALLY RECONSTITUTING A DRUG - Devices and methods are disclosed which automatically reconstitute a drug, such as e.g., a lyophilized drug. A vial ( | 11-07-2013 |
20130252941 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R | 09-26-2013 |
20130230585 | PHARMACEUTICAL COMPOUNDS - Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate. | 09-05-2013 |
20130171135 | METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY - The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods. | 07-04-2013 |
20130171134 | NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES - The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). | 07-04-2013 |
20130149237 | DELIVERY SYSTEM FOR DIAGNOSTIC AND THERAPEUTIC AGENTS - The invention provides shuttle agents and methods of using the same to facilitate the translocation of therapeutic or diagnostic molecules into the CNS. | 06-13-2013 |
20130123263 | BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomer solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-16-2013 |
20130121999 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. | 05-16-2013 |
20130115219 | Expression Vector - The present invention provides an expression vector for cell-surface expression of proteins. | 05-09-2013 |
20130109056 | Immunoglobulin aggregate removal | 05-02-2013 |
20130108626 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER | 05-02-2013 |
20130022596 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 01-24-2013 |
20120329151 | METHOD OF CULTURING EUKARYOTIC CELLS - An apparatus and method to maintain pH within a range conducive for cell growth in a bicarbonate-containing cell culture system without the addition of base. The method relies on the gas transfer characteristics of the bioreactor system to modulate the CO2 transfer to and from the cell culture such that the pH of the cell culture can be maintained within a desired range. | 12-27-2012 |
20120294866 | PHARMACEUTICAL FORMULATION FOR PROTEINS - The present invention provides a liquid pharmaceutical formulation comprising a therapeutic protein, a surfactant and at least an antioxidant selected from the group of radical scavengers, chelating agents or chain terminators. | 11-22-2012 |
20120283257 | PHARMACEUTICAL COMPOUNDS - Thienopyrimidines of formula (Ia) or (Ib): | 11-08-2012 |
20120208811 | Aminopyrazole Derivative - A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a C | 08-16-2012 |
20120172299 | PURIFICATION OF ERYTHROPOIETIN - In the present invention a method for purifying erythropoietin comprising at least one chromatography step using a stationary phase containing hydroxyapatite is reported. The method comprises the following steps i) the erythropoietin in a solution containing Calcium-ions is brought into contact with a stationary phase containing hydroxyapatite equilibrated with a solution containing Calcium-ions and namely under conditions under which the erythropoietin binds to the stationary phase containing hydroxyapatite, ii) a solution is passed over the stationary phase containing hydroxyapatite from i) which contains less Calcium-ions than the previous solution and the erythropoietin is not detached from stationary phase containing hydroxyapatite, and iii) a further solution which contains less than 0.5 mM Calcium-ions is passed over the stationary phase containing hydroxyapatite from ii) whereby the erythropoietin is detached from the stationary phase containing hydroxyapatite. | 07-05-2012 |
20120065892 | SCORING SYSTEM FOR THE PREDICTION OF CANCER RECURRENCE - The present invention relates to a scoring system for the prediction of cancer recurrence by selecting genes and/or proteins whose expression patterns associated with recurrence of cancer, and generating formulae with the selected genes and/or proteins for the prediction of cancer recurrence. The present invention relates to a kit for determining the likelihood of recurrence of cancer, comprising DNA chip, oligonucleotide chip, protein chip, peptides, antibodies, probes and primers that are necessary for effecting DNA microarrays, oligonucleotide microarrays, protein arrays, northern blotting, in situ hybridization, RNase protection assays, western blotting, ELISA assays, reverse transcription polymerase-chain reaction to examine the expression of at least 2, 4, 6, 10, 12 or more genes and/or proteins, that are indicative of cancer recurrence. | 03-15-2012 |
20110262950 | REDOX MEDIATORS - The present invention relates to ruthenium and osmium complexes of Formula [M(A) | 10-27-2011 |
20110223619 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE - Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 09-15-2011 |
20110177507 | OLIGONUCLEOTIDES FOR GENOTYPING THYMIDYLATE SYNTHASE GENE - Oligonucleotides for genotyping the thymidylate synthase gene are provided. The number of tandem repeats in the promoter region of the thymidylate synthase gene can be identified based on the hybridization of an oligonucleotide of the invention to the genomic DNA of a subject. Therefore, the genotype of the thymidylate synthase gene can be identified based on the number of tandem repeats. The genotype relates to the responsiveness of a subject towards an antitumor agent. | 07-21-2011 |
20110172216 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 07-14-2011 |
20110150829 | ANTIVIRAL NUCLEOSIDES - Compounds having the formula I wherein R | 06-23-2011 |
20110112085 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-12-2011 |
20110021496 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS - Thienopyrimidines of formula (I) wherein W and R | 01-27-2011 |
20100292247 | HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS - Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. | 11-18-2010 |
20100280027 | PHARMACEUTICAL COMPOUNDS - Provided herein are methods of treating diseases or disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, which method includes administering to a patient in need thereof a compound that is a fused pyrimidine of formula (I): | 11-04-2010 |
20100210646 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS - The invention provides a pyrimidine compound of formula (I): | 08-19-2010 |
20100130496 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE - The invention provides a pyrimidine compound of formula (I): | 05-27-2010 |
20100121036 | METHOD FOR THE PRODUCTION OF INSULIN-LIKE GROWTH FACTOR-1 - Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 05-13-2010 |
20100086440 | System and method for robotic storage of microplates - In some embodiments of the present disclosure, a robotic storage system for storing microplates carrying a plurality of sample tubes is provided and may comprise a freezer room having a plurality of freezing units and a first robot being capable of removing a microplate from and moving a microplate into a freezing unit. The first robot may be further capable of transferring the microplate to a processing station, where the microplates are stored in the freezing units such that a plurality of microplates are arranged one above the other in a microplate recipient. The robotic storage system may also include at least one processing room and means for thermally separating the processing room from the freezer room. Each processing room may include a processing station having at least one tube transfer module as well as a second robot for moving the microplates between the microplate recipients and the at least one tube transfer module. The first robot may be designed such that it is only capable of removing a microplate recipient from and moving it into a said freezing unit as well as of transferring it from a freezing unit to a processing station or vice versa. | 04-08-2010 |
20100068100 | Sample Carrier - Some embodiments of the present disclosure include a sample carrier for biologically active samples, in particular for toxic samples and especially for highly toxic samples. Such embodiments include a bottom part, a first membrane, a spacer, a second membrane and a lid. The bottom part and the lid may be connectable such that the first membrane, the spacer and the second membrane are enclosed between the bottom part and the lid. The bottom part and the lid may include means for a non-detachable form-locking connection between the bottom part and the lid. | 03-18-2010 |
20100031685 | Convection Barrier - Embodiments of the present invention include a convection barrier for a freezer which may comprise a plurality of individual flaps arranged one above the other in a manner such as to be capable of forming a closed curtain of individual flaps, with each individual flap extending over a predetermined width corresponding at least to the width of the interior of the freezer and being pivotable between a closed position and an open position so as to allow access to the interior of the freezer when the flap is in the open position. Embodiments may also include actuation means attached to the individual flaps for allowing an actuator to engage the actuation means of an individual flap so as to pivot the said flap between the closed position and the open position. | 02-11-2010 |
20100016306 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS - Thienopyrimidines of formula (Ia) or (Ib): | 01-21-2010 |
20100005826 | Convection barrier - A convection barrier for a freezer is disclosed. The convection barrier may include a foil having at least one opening therein, storage and transport means for storing and moving the foil so as to transport the at least one opening to a desired position allowing access through the at least one opening to the interior of the freezer at the desired position and tensioning means for continuously keeping the foil in a tensioned state. | 01-14-2010 |
20090209559 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 08-20-2009 |
20090199510 | Crimping Device - A crimping device for crimping a cap around a flange of a container is provided. The crimping device comprises a disc having a first disc member and a second disc member adjacent the first disc member, wherein the second disc member extends outwardly beyond the first disc member and has a hardness lesser than that of the container and a motion device for producing a relative movement between the disc and the flange of the container so as to effect crimping of the cap around the flange. | 08-13-2009 |
20090187365 | Method for Assessing Absorption Properties of Low Solubility Compounds - The invention deals with a method for the assessment of the effect of excipients, pH and combinations thereof on the predicted absorption properties of low solubility compounds, comprising the step of assessing a change in a flux function for a combination of a low solubility compound and an excipient at at least one predefined pH value. The method allows a fast, accurate, and economic evaluation of an excipient being capable of optimizing the absorption of drug molecules, i.e. low solubility compounds. Furthermore, animal experiments can be excluded and use of compounds can be reduced in such evaluation. Thus, screening for future formulation efficacy (pH and excipient effects on solubility and permeability) of drug candidates can be justified, since the method is fast, compound-sparing, cost-effective, and reasonably accurate. | 07-23-2009 |
20090143375 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents - Objects of the present invention are the compounds of formula I | 06-04-2009 |
20090118275 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 05-07-2009 |
20090098660 | Method for the Purification of Antibodies - A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described. | 04-16-2009 |
20080281847 | METHOD OF PROCESSING PROTEIN PEPTIDE DATA AND SYSTEM - The invention provides a method of processing protein peptide data obtained from healthy or pathological samples for analysis, comprising the steps of: providing a list of peptide sequences and associated auxiliary information representing an input data set; compiling from the input data set a new peptide sequence list by removing peptide sequence redundancy in the peptide sequence list, said new peptide sequence list representing a peptide data set; and grouping together members of the peptide data set originating from the same protein thus generating a protein data set. | 11-13-2008 |
20080270040 | Automated generation of multi-dimensional structure activity and structure property relationships - The present invention relates to automated generation of multi-dimensional structure activity and structure property relationships. | 10-30-2008 |
20080260511 | Stacker - A stacker ( | 10-23-2008 |
20080245970 | Sorption Micro-Array - A sorption micro-array ( | 10-09-2008 |